Online citations, reference lists, and bibliographies.
Please confirm you are human
(Sign Up for free to never see this)
← Back to Search

A Novel Combination Of Soluplus®/Poloxamer For Meloxicam Solid Dispersions Via Hot Melt Extrusion For Rapid Onset Of Action. Part 2: Comparative Bioavailability And IVIVC

N. F. Taha, M. Emam, L. Emara
Published 2020 · Chemistry, Medicine

Save to my Library
Download PDF
Analyze on Scholarcy
Share
Abstract Objective Bioavailability of Meloxicam (MLX) from solid dispersions (SDs), against innovator product Mobic® in humans was conducted. Furthermore, to establish a good in vitro–in vivo correlation (IVIVC); dissolution studies were carried-out in different media. Methods MLX/SDs was prepared using Soluplus/Poloxamer via hot-melt-extrusion (EXT-SD) and fusion melt (FUS-SD) techniques. A single oral dose (15 mg), three periods, crossover study of MLX/SDs and Mobic® in four healthy humans under fed conditions was carried-out. In vitro dissolution was studied in pH 1.2, distilled water (pH 6.4), and biorelevant simulated gastric media in pre- and post-prandial states. Level A IVIVC was carried-out by comparing time-scaled fraction dissolved versus fraction absorbed and calculated using the Wagner-Nelson method. Multiple level C models were developed for C max and AUC0–96 versus % dissolved at different time-points. Internal predictability was evaluated for both IVIVC models. Results MLX rate of absorption (T max) from EXT-SD, FUS-SD, and Mobic® was 1.5, 3.0, and 4.0 h, respectively. Moreover, 1.45- and 1.40-folds increase in AUC0–∞ and C max, was obtained for EXT-SD versus Mobic®, respectively, while FUS-SD gave the lowest extent of drug absorption. EXT-SD provided highest dissolution profiles in all studied media. IVIVC models showed linear-regression (R 2≥0.90) and prediction errors (≤10%) in water and post-prandial simulated gastric media. Conclusion Hot-melt-extrusion technology promises an ideal alternative for enhancing MLX extent of absorption compared to Mobic® with T max value almost equal to the reported intramuscular injection. Predictive IVIVC was established for in vitro dissolution profile and in vivo performance.
This paper references
10.2174/157341210793292400
The Progress on the In Vivo-In Vitro Correlation (IVIVC) for Immediate Release Dosage Form as an Alternative to Bioavailability Studies
Michal Ostrowski and Tomasz Baczek (2010)
10.1016/j.ijpharm.2015.05.054
Developing dissolution testing methodologies for extended-release oral dosage forms with supersaturating properties. Case example: Solid dispersion matrix of indomethacin.
Tomokazu Tajiri (2015)
10.1208/s12248-010-9203-3
The Use of Biorelevant Dissolution Media to Forecast the In Vivo Performance of a Drug
S. Klein (2010)
10.1007/978-0-387-69154-1_6
Biorelevant Dissolution Media
A. Müllertz (2007)
Characterizing release from lipid-based formulations. In: Hauss DJ, editor. Oral lipid-based formulations: enhancing the bioavailability of poorly water-soluble drugs
J Dressman (2007)
10.3109/9781420017267
Oral Lipid-Based Formulations: Enhancing the Bioavailability of Poorly Water-Soluble Drugs
J. Dressman (2007)
10.1016/j.ijpharm.2011.01.010
In vitro-in vivo correlation: perspectives on model development.
Y. Lu (2011)
10.7324/JAPS.2016.60702
A Simple and Sensitive HPLC/UV Method for Determination of Meloxicam in Human Plasma for Bioavailability and Bioequivalence Studies -
L. Emara (2016)
10.1002/jps.22472
Investigation on the possibility of biowaivers for ibuprofen.
C. Álvarez (2011)
10.1016/j.ejpb.2009.05.009
Prediction of food effects on the absorption of celecoxib based on biorelevant dissolution testing coupled with physiologically based pharmacokinetic modeling.
Y. Shono (2009)
10.1111/jphp.12859
Evaluating bioequivalence of meloxicam tablets: is in‐vitro dissolution test overdiscriminating?
Chan Jin (2018)
10.1093/RHEUMATOLOGY/35.SUPPL_1.13
A review of the clinical pharmacokinetics of meloxicam.
D. Tuerck (1996)
10.1002/jps.22209
The influence of averaging procedure on the accuracy of IVIVC predictions: immediate release dosage form case study.
M. Ostrowski (2010)
10.1002/JPS.1071
In vitro-in vivo correlation (IVIVC) models for metformin after administration of modified-release (MR) oral dosage forms to healthy human volunteers.
G. Bălan (2001)
10.1081/DDC-100100352
In Vitro-In Vivo Correlation and Comparative Bioavailablity of Vincamine in Prolonged-Release Preparations
L. H. Emara (2000)
10.1016/S1570-0232(02)00862-0
Sensitive and rapid liquid chromatography-tandem mass spectrometry method for the determination of meloxicam in human plasma.
J. Wiesner (2003)
10.1016/j.xphs.2017.05.023
Amorphous Solid Dispersion of Meloxicam Enhanced Oral Absorption in Rats With Impaired Gastric Motility.
H. Suzuki (2018)
10.1002/JPS.20444
Biowaiver monographs for immediate release solid oral dosage forms: ibuprofen.
H. Potthast (2005)
10.2147/TCRM.S39024
Comparative pharmacokinetic and pharmacodynamic evaluation of branded and generic formulations of meloxicam in healthy male volunteers
M. Tacca (2013)
10.14227/DT190412P36
Development and Validation of a Dissolution Method for Pioglitazone Tablets
A. P. Kulkarni (2012)
Solvent Systems And Their Selection In Pharmaceutics And Biopharmaceutics
Julia Eichmann (2016)
10.1016/S0928-0987(00)00181-0
In vitro-in vivo correlations for lipophilic, poorly water-soluble drugs.
J. Dressman (2000)
10.1016/S0928-0987(01)00095-1
Modeling and comparison of dissolution profiles.
P. Costa (2001)
10.2165/00019053-199200011-00012
Comparative Potency and Dissolution Performance of Internationally Available Piroxicam Products
J. Barone (2012)
10.1016/j.ejpb.2015.03.009
In-vitro simulation of luminal conditions for evaluation of performance of oral drug products: Choosing the appropriate test media.
C. Markopoulos (2015)
10.1007/PL00000219
Meloxicam oral suspension: a treatment alternative to solid meloxicam formulations
G. Hanft (2001)
10.1016/J.JCHROMB.2007.09.004
Determination of meloxicam in human plasma using a HPLC method with UV detection and its application to a pharmacokinetic study.
J. Bae (2007)
10.1177/009286157000400250
Biopharmaceutics and Relevant Pharmacokinetics
J. Wagner (1971)
10.14227/DT130106P6
Comparison of Drug Release From Metoprolol Modified Release Dosage Forms in Single Buffer versus a pH-Gradient Dissolution Test
S. Klein (2006)
Centre for Drug Evaluation and Research (CDER), US Department of Health and Human Services
Fda Guidance For Industry (1997)
10.1002/jps.24036
In vitro-in vivo correlation strategy applied to an immediate-release solid oral dosage form with a biopharmaceutical classification system IV compound case study.
Gerard M Bredael (2014)
10.1016/J.SUPFLU.2006.12.024
Micronization of meloxicam using a supercritical fluids process
A. H. Chiou (2007)
10.2174/1874126601004010002
Biorelevant dissolution methods and their applications in in vitroin vivo correlations for oralformulations
N. Fotaki (2010)
10.1111/J.1365-2125.1996.TB00171.X
Pharmacokinetics and tolerability of meloxicam after i.m. administration.
H. Narjes (1996)
10.1248/BPB.31.1946
Extended release dosage form of glipizide: development and validation of a level A in vitro-in vivo correlation.
Animesh Ghosh (2008)
10.1023/A:1016473601633
Biopharmaceutics Classification System: The Scientific Basis for Biowaiver Extensions
L. Yu (2004)
10.1002/BDD.446
Bioequivalence evaluation of two brands of meloxicam tablets (promotion® and mobicox®): pharmacokinetics in a healthy female Mexican population
G. Marcelín-Jiménez (2005)
10.1016/j.ejps.2009.03.015
Application of biorelevant dissolution tests to the prediction of in vivo performance of diclofenac sodium from an oral modified-release pellet dosage form.
E. Jantratid (2009)
10.1002/jps.23799
Biowaiver monographs for immediate release solid oral dosage forms: piroxicam.
I. Shohin (2014)
IN-VITRO DISSOLUTION STUDY OF MELOXICAM IMMEDIATE RELEASE PRODUCTS USING FLOW THROUGH CELL (USP APPARATUS 4) UNDER DIFFERENT OPERATIONAL CONDITIONS
L. Emara (2014)
10.1002/jps.23233
Biowaiver monographs for immediate-release solid oral dosage forms: ketoprofen.
I. Shohin (2012)
10.1023/A:1011071401306
Biorelevant Dissolution Testing to Predict the Plasma Profile of Lipophilic Drugs After Oral Administration
E. Nicolaides (2004)
In vitro and in vivo evaluations of dosage forms
(2007)
Biopharmaceutics and relevant pharmacokinetics. Hamilton: Drug Intelligence
J G Wagner (1981)
10.1023/A:1018959511323
Forecasting the In Vivo Performance of Four Low Solubility Drugs from Their In Vitro Dissolution Data
E. Nicolaides (2004)
Biowaiver monographs for immediate release solid oral dosage forms: DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY 1371 diclofenac sodium and diclofenac potassium
B Chuasuwan (2009)
10.1016/J.EJPB.2005.03.002
Simulation of fasting gastric conditions and its importance for the in vivo dissolution of lipophilic compounds.
M. Vertzoni (2005)
10.1023/A:1011910801212
Evaluation of Various Dissolution Media for Predicting In Vivo Performance of Class I and II Drugs
E. Galia (2004)
Pharmacokinetics of meloxicam in animals and the relevance to humans.
U. Busch (1998)
FDA Guidance for Industry: bioanalytical method validation, US Department of Health and Human Services
(2001)
In vitro in vivo correlation models for metformin after administration of modified release (MR) oral dosage forms to healthy human volunteers
B Guhan (2001)
10.1016/S0378-5173(02)00645-2
Effect of buffer media composition on the solubility and effective permeability coefficient of ibuprofen.
K. Levis (2003)
Effect of compaction pressure on the dissolution efficiency of some direct compression systems.
K. A. Khan (1972)
10.4274/tjps.87587
Development, Internal and External Validation of Naproxen Sodium Sustained Release Formulation: an Level A In Vitro-In Vivo Correlation
Ramesh Narayanasamy (2017)
10.1201/9780824741969.AXD
Extended Release Oral Dosage Forms—Development,Evaluation, and Application of In Vitro/In Vivo Correlations
M. Levin (2001)
10.1208/s12249-011-9718-7
Preparation and In Vitro/In Vivo Evaluation of Microparticle Formulations Containing Meloxicam
H. Eroğlu (2011)
Clinical pharmacokinetics of meloxicam. A cyclo-oxygenase-2 preferential nonsteroidal antiinflammatory drug
NM Davies (1999)
DISCRIMINATORY POTENTIAL OF BIPHASIC MEDIUM OVER COMPENDIAL AND BIORELEVANT MEDIUM FOR ASSESSMENT OF DISSOLUTION BEHAVIOR OF TABLETS CONTAINING MELOXICAM NANOPARTICLES
Ranjith Anishetty (2016)
10.1016/j.ejpb.2007.12.013
Using biorelevant dissolution to obtain IVIVC of solid dosage forms containing a poorly-soluble model compound.
Bena-Marie Lue (2008)
Bioequivalence study of two brands of meloxicam tablets in healthy human Pakistani male subjects.
M. Ahmad (2011)
10.1211/0022357022935
Dissolution media simulating the intralumenal composition of the small intestine: physiological issues and practical aspects
M. Vertzoni (2004)
10.1016/j.ijpharm.2020.119210
In vitro - in vivo correlation in the development of oral drug formulation: A screenshot of the last two decades.
M. G. Davanço (2020)
Mathematical comparison of dissolution profiles
J. S. Moore (1996)
10.1002/jps.21525
Biowaiver monographs for immediate release solid oral dosage forms: diclofenac sodium and diclofenac potassium.
B. Chuasuwan (2009)
10.1002/JPS.2600821116
In vivo evaluation of controlled-release products.
S. Hwang (1993)
10.1007/PL00022377
Meloxicam: a review of its pharmacokinetics, efficacy and tolerability following intramuscular administration
L. Euller-Ziegler (2001)
10.1016/0928-0987(95)00046-1
Structure and physicochemical properties of meloxicam, a new NSAID
P. Luger (1996)
10.1007/s11095-008-9569-4
Dissolution Media Simulating Conditions in the Proximal Human Gastrointestinal Tract: An Update
E. Jantratid (2008)
Guideline on quality of oral modified release products
(2012)
10.2174/1874126601004020002
Biorelevant Dissolution Methods and Their Applications in In Vitro- In Vivo Correlations for Oral Formulations~!2009-09-14~!2009-11-02~!2010-04-29~!
N. Fotaki (2010)
10.1016/j.ejpb.2007.12.010
Designing biorelevant dissolution tests for lipid formulations: case example--lipid suspension of RZ-50.
E. Jantratid (2008)
FDA Guidance for Industry: dissolution testing of immediate-release solid oral dosage forms. US Department of Health and Human Services, FDA
(1997)
Biorelevant media to simulate postprandial conditions in the proximal gut
N Janssen (2007)
10.1016/S0731-7085(98)00011-9
An evaluation of fit factors and dissolution efficiency for the comparison of in vitro dissolution profiles.
N. Anderson (1998)
10.1023/A:1011984216775
Dissolution Testing as a Prognostic Tool for Oral Drug Absorption: Immediate Release Dosage Forms
J. Dressman (2004)
10.2165/00003088-199936020-00003
Clinical Pharmacokinetics of Meloxicam
N. M. Davies (1999)



This paper is referenced by
Semantic Scholar Logo Some data provided by SemanticScholar